# EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
> **ANDA220232** · Abbreviated New Drug Application (Generic) · Sponsor: LAURUS · Approved 2026-03-04
## Drug
- **FDA Application Number:** ANDA220232
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Active ingredients:** EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** LAURUS
- **Manufacturer:** Laurus Labs Limited
- **First approval:** 2026-03-04
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220232)
---
*AI Analytics · CC0 1.0*